Mylan’s Nashik, India facility produces the company’s finished-dosage-form ARVs for markets around the world including India.
Mylan CEO Heather Bresch said the company can set a new standard in the treatment of HIV/AIDS in India by providing healthcare providers and those living with the disease access to high quality, affordable medicines and by supporting physicians in their efforts to educate and treat their patients through the innovation, reliability and service excellence.
"We see significant growth potential in India, the world’s second largest pharmaceutical market by volume, and look forward to continuing to expand our operations in India in additional therapeutic categories," Bresch added.
The Nashik facility has been subject to Good Manufacturing Practices inspections by several regulatory authorities, including the FDA and the World Health Organization.
Mylan also has introduced a number of ARV innovations, for example producing single blister combo packs, which provide a reduced pill burden and once-a-day dosage, according to the company.
Mylan expects to add additional therapeutic categories, build out its sales force across India and launch several initiatives aimed at educating and supporting medical professionals.